Naegis is attending ARVO 2024   May 5th 9th  |  Seattle

Our Science

New Targets

Leukotrienes (LTs) are central to the inflammatory processes that damage the eye. There are two branches of the pathway that lead to the production of leukotrienes:

LTB4 branch
LTB4 is one of the most potent chemokines known. Chemokines are molecules that “call” cells to the site of inflammation.

Cysteinyl (cys) branch
cysLTs are known to be among the most potent inflammatory molecules to induce vascular permeability. In disease, vascular permeability is a process that allows for the leakage of fluid and cells into tissue resulting in inflammation and damage.

LTB4 branch
LTB4 is one of the most potent chemokines known. Chemokines are molecules that “call” cells to the site of inflammation.

Cysteinyl (cys) branch
cysLTs are known to be among the most potent inflammatory molecules to induce vascular permeability. In disease, vascular permeability is a process that allows for the leakage of fluid and cells into tissue resulting in inflammation and damage.

In blocking the production of both LTB4 and cysLTs, Naegis’ strategy is to block the “calling of cells” to the eye as well the leakage of these cells and fluid into the inflamed eye tissue.

Recent literature evidence demonstrates that both LTB4 and cysLTs drive inflammation in both front of the eye and back of the eye diseases.

New Molecules

Naegis designed and synthesized a novel class of small molecules that block both LTB4 and cysLT production. Among a number of lead candidates in its proprietary library, Naegis has selected N0651 as the first compound to advance to clinical development.

N0651
is a potent inhibitor of leukotriene production

New Therapies

Front of Eye

N0651 protects the cornea from damage.

Damaged Cornea

Cornea Treated with N0651 Administered Orally

Back of Eye

N0651 protects the retina from damage.

Normal Retina

Damaged Retina

Damaged Retina Protected by N0651 Administered by Eye Drops